Abstract:Macroautophagy/autophagy is an evolutionarily conserved pathway responsible for clearing cytosolic aggregated proteins, damaged organelles or invading microorganisms. Dysfunctional autophagy leads to pathological accumulation of the cargo, which has been linked to a range of human diseases, including neurodegenerative diseases, infectious and autoimmune diseases and various forms of cancer. Cumulative work in animal models, application of genetic tools and pharmacologically active compounds, has suggested the potential therapeutic value of autophagy modulation in disease, as diverse as Huntington, Salmonella infection, or pancreatic cancer. Autophagy activation versus inhibition strategies are being explored, while the role of autophagy in pathophysiology is being studied in parallel. However, the progress of preclinical and clinical development of autophagy modulators has been greatly hampered by the paucity of selective pharmacological agents and biomarkers to dissect their precise impact on various forms of autophagy and cellular responses. Here, we summarize established and new strategies in autophagy-related drug discovery and indicate a path toward establishing a more efficient discovery of autophagy-selective pharmacological agents. With this knowledge at hand, modern concepts for therapeutic exploitation of autophagy might become more plausible.Abbreviations: ALS: amyotrophic lateral sclerosis; AMPK: AMP-activated protein kinase; ATG: autophagy-related gene; AUTAC: autophagy-targeting chimera; CNS: central nervous system; CQ: chloroquine; GABARAP: gamma-aminobutyric acid type A receptor-associated protein; HCQ: hydroxychloroquine; LYTAC: lysosome targeting chimera; MAP1LC3/LC3: microtubule associated protein 1 light chain 3; MTOR: mechanistic target of rapamycin kinase; NDD: neurodegenerative disease; PDAC: pancreatic ductal adenocarcinoma; PE: phosphatidylethanolamine; PIK3C3/VPS34: phosphatidylinositol 3-kinase catalytic subunit type 3; PtdIns3K: class III phosphatidylinositol 3-kinase; PtdIns3P: phosphatidylinositol 3-phosphate; PROTAC: proteolysis-targeting chimera; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; SQSTM1/p62: sequestosome 1; ULK1: unc-51 like autophagy activating kinase 1.

Targeting autophagy in neurodegenerative diseases: From molecular mechanisms to clinical therapeutics

Autophagy in Aging and Neurodegenerative Diseases: Implications for Pathogenesis and Therapy.

Targeting Autophagy for the Treatment of Alzheimer’s Disease: Challenges and Opportunities

Autophagy and apoptosis dysfunction in neurodegenerative disorders

Autophagy in Alzheimer’s disease pathogenesis: Therapeutic potential and future perspectives

Molecular targets and approaches to restore autophagy and lysosomal capacity in neurodegenerative disorders

The Potential of Targeting Autophagy-Related Non-coding RNAs in the Treatment of Alzheimer's and Parkinson's Diseases

Role of autophagy and proteostasis in neurodegenerative diseases: Exploring the therapeutic interventions

Impairment of the autophagy–lysosomal pathway in Alzheimer's diseases: Pathogenic mechanisms and therapeutic potential

Autophagy Modulation for Alzheimer's Disease Therapy.

Autophagy in Neurodegenerative Diseases: A Hunter for Aggregates

Compromised autophagy and neurodegenerative diseases

MicroRNAs regulating autophagy: opportunities in treating neurodegenerative diseases

Defective Autophagy and Mitophagy in Alzheimer's Disease: Mechanisms and Translational Implications

Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease

Autophagy in Axonal and Dendritic Degeneration

Autophagy, aging, and age-related neurodegeneration

Targeting autophagy in disease: established and new strategies

Autophagy and Its Comprehensive Impact on ALS

Natural Compounds and Autophagy: Allies Against Neurodegeneration

Autophagy-Lysosomal Pathway as Potential Therapeutic Target in Parkinson's Disease